Table 1 Demographical and clinical characteristics of patients

Age (years)

47

52

39

31

34

32

Sex

female

male

female

female

female

female

Disease duration (months)

203

309

165

105

89

167

Prior therapies

IFN-beta1b

IFN-beta1a s.c.; IFN-beta1a i.m.;

cyclophosphamide

None

None

fingolimod

IFN-beta1a i.m.

N of relapses at MS diagnosis

3

2

2

2

3

2

N of relapses in the year before starting NTZ

1

2

2

2

1

1

N of relapses during NTZ

0

0

0

0

0

0

EDSS at onset

4.5

2.5

3.5

1.0

1.5

6.0

EDSS before at NTZ initiation

5.0

2.0

3.5

0.0

1.5

4.0

EDSS before COVID infection^a

5.0

4.5

3.5

0.0

0.0

6.0

N of new/enlarged/Gd-enhanced lesions at MS diagnosis

0

0

0

2

3

4

N of new/enlarged/Gd-enhanced lesions at NTZ initiation

0

0

0

0

0

1

N of new/enlarged/Gd + −enhanced lesions before COVID-19^a

0

0

0

0

0

0

N of new/enlarged/Gd + −enhanced lesions after COVID-19^b

0

0

0

0

0

0

N of NTZ administrations before COVID-19

28

69

18

13

57

62

JCV status^a

negative

negative

positive (1.07)

negative

negative

negative

Comorbidities

none

myxoid liposarcoma ^c

none

none

none

none

Smoker

no

yes

no

yes

no

no

BMI

21.6

25.6

24.3

27.1

21.3

25.0